Humacyte, Inc. SEC filings HUMA

Humacyte, Inc. has 504 filings in SEC EDGAR's recent list, going back to Aug 4, 2020. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Apr 28, 2026 Apr 28, 2026
PRE 14A Preliminary proxy statement Apr 17, 2026 Apr 17, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 10, 2025
PRE 14A Preliminary proxy statement Apr 17, 2025 Jun 10, 2025
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 11, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 7, 2023
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 9, 2022

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
HUMA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Durham, NC
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1818382
Former names
Alpha Healthcare Acquisition Corp. (until Aug 26, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.